Overview
Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017. It was also approved by the European Commission in March 2018.
Indication
Ertugliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus (T2DM). It is also available in combination with either metformin or sitagliptin. Ertugliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
Associated Conditions
- Type 2 Diabetes Mellitus
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2022/12/09 | Phase 4 | Recruiting | Getz Pharma | ||
2021/12/10 | Phase 4 | Recruiting | |||
2020/10/23 | Phase 3 | Terminated | Medical University of Graz | ||
2020/07/29 | Phase 3 | UNKNOWN | |||
2020/06/18 | Phase 2 | Recruiting | |||
2020/01/18 | Phase 3 | Completed | |||
2019/11/19 | Early Phase 1 | Completed | |||
2019/08/28 | Phase 4 | Terminated | |||
2019/07/23 | Phase 3 | Completed | |||
2019/07/22 | Phase 4 | Completed | Amsterdam UMC, location VUmc |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
No NMPA approvals found for this drug. |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
---|---|---|---|---|---|
STEGLATRO | Merck Canada Inc | 02475510 | Tablet - Oral | 5 MG | 5/28/2018 |
SEGLUROMET | Merck Canada Inc | 02476258 | Tablet - Oral | 7.5 MG | 7/6/2018 |
STEGLUJAN | Merck Canada Inc | 02475901 | Tablet - Oral | 5 MG | 6/13/2018 |
SEGLUROMET | Merck Canada Inc | 02476231 | Tablet - Oral | 7.5 MG | 7/6/2018 |
STEGLATRO | Merck Canada Inc | 02475529 | Tablet - Oral | 15 MG | 5/28/2018 |
SEGLUROMET | Merck Canada Inc | 02476215 | Tablet - Oral | 2.5 MG | 7/6/2018 |
SEGLUROMET | Merck Canada Inc | 02476223 | Tablet - Oral | 2.5 MG | 7/6/2018 |
STEGLUJAN | Merck Canada Inc | 02475928 | Tablet - Oral | 15 MG | 6/13/2018 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
---|---|---|---|---|---|
No CIMA AEMPS (Spain) approvals found for this drug. |
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Philippines FDA approvals found for this drug. |
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Saudi SFDA approvals found for this drug. |
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No Malaysia NPRA approvals found for this drug. |
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
---|---|---|---|---|---|
No UK EMC drug information found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.